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ABSTRACT
Though it is well known that tobacco related products can cause prenatal
maldevelopment, very little is known on how tobacco products affect bone tissue
as it develops in the embryo. Identifying which chemicals can induce the greatest
harm to the prenatal skeletal system is an improbable task as there are over
7,000 chemicals in tobacco smoke alone. We hypothesized that the Toxicological
Priority Index (ToxPI) program can be used to rank osteogenic cytotoxicity
potential to aid in the assessment of what chemicals out of the thousands can
cause osteogenic differentiation inhibition. ToxPI aggregates information from
various assays and incorporates them into visual “pie charts” which allow
chemicals to be ranked against each other by given parameters. The larger the
pie chart the greater likelihood of potential effects and vice versa. Seventeen
tobacco chemical constituents were ranked using ToxPI and those chemicals
with pie charts (0<X) are predicted to have decreased cell viability and
differentiation capabilities where chemicals with null pie charts (x=0) will not have
any effects.
To assess the ability of ToxPI to correctly predict maldevelopment in silico
eight compounds were then tested in vitro: four of them being ToxPi positive and
the other four having null predicted effects. To verify the predictions, human
embryonic stem cells were differentiated into osteoblasts and exposed to various
concentrations of each compound. Cell viability was measured via MTT assay in
conjunction with a calcium assay to measure osteogenic differentiation. In
iii

addition, adult human feeder fibroblasts cell viability in response to exposure was
measured. ToxPI positive predictions (x<0) all exhibited decreased cell viability
though in various order. All tested ToxPI null charts produced no change in cell
viability. However, one of the ToxPI null chemicals, nicotine, although not
cytotoxic in vitro, caused differentiation inhibition. Together our data suggests
that ToxPi might be useful to identify strongly inhibitory chemicals based on their
cytotoxicity but might also give false negative results for chemicals that cause
differentiation inhibition at sub-toxic levels.
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CHAPTER ONE
INTRODUCTION

Health Consequences of Exposure to Tobacco
The environment plays a prominent role in human health as it could
negatively impact all stages of life. The World Health Organization (WHO)
estimates 24% of the global disease burden and 23% of all deaths to be
attributed to environmental factors.1 Environmental factors can come in the
means of biological, chemical, and radioactive substances. For instance,
continuous use of medications such as valproate have been associated with
short stature2, and supplemental addition of retinoic acid in the diet of a pregnant
mother has been linked to craniofacial abnormalities.3 With the potential to alter
and harm human health it is of great importance to study and assess a
chemical’s range of potential outcomes in the absence of an acquired disease or
genetic predisposition.
The most common environmental and indoor toxicant is exposure to
smoke via cigarettes. Such exposure can be through mainstream smoke (MS)
that is actively inhaled by the user, side stream smoke (SS), which burns off the
ends of cigarettes, and third hand smoke (THS) that consists of left-over
particulate matter that can rest in clothing, carpets, and any outdoor or indoor
surfaces. In addition, exposure can happen orally through use of noncombustible
tobacco products such as chewing tobacco. All these tobacco products are
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known to cause a broad spectrum of health effects. In adults, its use is
associated with an increased risk of gum disease, blindness, reduced fertility in
addition to respiratory complications and cardiovascular disease. Smoking is
strongly associated with cancers that are not limited to the head, neck, lung,
bladder, stomach, and colon.4 Tobacco products overall will reduce human
health: if every smoker decided to stop smoking, one in three cancer deaths
would cease to exist.3 The Center for Disease Control (CDC) estimates that one
in five deaths in the United States can be attributed to cigarette smoking and is
responsible for 480,000 deaths annually.4 In addition to disease, the total
economic cost of smoking is 300 billion dollars a year in the United States alone. 5
Exposure to tobacco products can also induce tissue specific effects as seen in
adult bone. Smoking has been shown to disrupt osteogenesis and can lead to
osteoporosis, an increase in bone fragility, and an overall delay in bone healing.6
Despite these known health consequences of tobacco use, 10-20% of
pregnant women report smoking during their first trimester of pregnancy. 7
Smoking during pregnancy is linked to premature birth, sudden infant death
syndrome, low birth weight, and ectopic pregnancy4, but whether tobacco
exposure is harmful to the developing skeleton is understudied. However,
perpetrating bone growth and density could have irreversible effects on the
development of the fetus and pose a significant threat to the baby’s health
postpartum as evidence suggests skeletal growth is programmed very early in
development. In fact, a few years ago, Rasmussen reported that while tobacco
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exposure may not lead to premature death, it can still perturb development to
cause a birth defect.8

Skeletal Development
The skeleton protects critical organs such as the brain in addition to
providing a scaffold, which the body rests upon. The axial skeleton provides the
core of the skeletal system and consists of the spinal column, and ribcage. The
appendicular skeleton encompasses the extremities of the skeletal system, but
also include the pelvic and pectoral girdle along with the clavicles. Skeletal
development post fertilization starts from anterior to posterior, essentially starting
from the skull descending to the spinal column while filling out the rib cage. The
extremities of the body develop from the pelvic and pectoral girdles and extend
out laterally.9 Two bone development processes are responsible for formation of
the skeleton: intramembranous and endochondral ossification. Neural crest
derived mesenchymal precursors undergo intramembranous ossification, which
is a direct bone formation process. Parts of the skull and clavicles develop bone
through intramembranous ossification. Cells from a mesoderm mesenchymal
origin use endochondral ossification that uses a temporary cartilage placeholder
that is eventually replaced with bone, as seen in many long bones. The
appendicular skeleton and base of the skull is primarily produced via this type of
ossification.10 Once developed, osteoblasts, the bone forming cells, and
osteoclasts, which resorp the bone matrix, are the predominant cell types in bone
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and their interaction drives bone remodeling. The skeleton is continuously
restructured and grows in both diameter and length post birth continuing into
adolescence.11

Developmental Biology
Developmental biology studies the initiation and construction of the
organism as a developing embryo. This is contrary to other fields of biology that
focus on maintenance and repair of adult organisms. Studying embryonic
development can help shed light on the process of how organisms differentiate,
organize, and grow before birth. This transient stage between egg and sperm
into a functioning organism is critical as this developmental period is relatively
quick and short. During this limited time frame a major question of how
environmental cues impact the developmental process needs to be assessed.
Most mammal keep their embryos inside of themselves and exposure to
environmental agents through the mother will impact the development of the
embryo as well. This is a major concern as the use of chemicals has increased in
various sectors of transport, agriculture, and industry. WHO estimates that
47,000 deaths annually can be directly attributed to chemical exposure. In the
absence of fatal exposure, teratogens are of great concern. Teratogens are
agents that can disturb development of the embryo and produce a birth defect.
This is especially alarming as the number of birth defects have been increasing
in the United States by 150,000 a year.12 These defects have ranged from limb
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reduction, cardiac malformation and impaired neural development. In summary,
the study of development is necessary, as it adds depth to other biological
disciplines such as cell biology, anatomy, and genetics.

Embryonic Stem Cells
Embryonic stem cells (ESCs) are unspecialized pluripotent cells, that give
rise to all specialized cells within the body (Figure 1). This pluripotency allows
ESCs to differentiate into the three germ layers (endoderm, mesoderm,
ectoderm), which encompass over 200 cell types.13 However, ESCs do not give
rise to extraembryonic tissues, such as the placenta, and can only develop the
embryo proper. Derived from the inner cell mass of the blastocyst at day 5 post
fertilization, ESCs can be isolated and plated to grow in laboratory conditions. In
culture, ESCs self-renew and replicate themselves into the same non-specialized
cell continuously for long periods of time, a state that is maintained by the
presence of a triad of transcription factors composed of OCT4, SOX2, and
NANOG, which co-occupy regions of ESC chromatin to activate pluripotency
genes and repress differentiation genes.14,15
With the suppression of pluripotency markers, it is possible for ESCs to
begin to differentiate into other cell types. In a non-adherent environment, ESCs
can be forced to aggregate and form embryoid bodies, which contain
differentiating cells of all three germ layers. The aggregation of ESCs in
suspension is commonly referred to as the hanging drop method. When plated
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on an adherent surface, embryoid bodies spontaneously differentiate into a
variety of cell types, one of the most prominent being cardiomyocytes that can
contract with synchronistic rhythmic activity.16 To help drive ESCs to other cell
lineages and fates chemicals can be supplemented in culture.
The potential use of ESC is a remarkable tool that allows predictability
through in vitro results. Murine ESC have been harvested and used since 1981
but it was not until the late 1990s that the first human stem cells were isolated.
Adult stem cells differ from ESC as their differentiation potential to
produce the germ layers of the body is limited and reduced to certain organs or
tissues due to the pluripotency transcription triad being altered or absent. Due to
this limited differentiation potentially, adult stem cells are considered multi- or unipotent. In addition to a reduced amount of lineage potential, adult stem cells do
not have unlimited proliferative potential and do have a finite limit to replace cells.
With the limited ability to create certain cell types adult stem cells are only able to
differentiate and replace those tissues from where they are found. So far adult
stem cells have been found in mesenchymal, hematopoietic, and neural
tissues.17
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Figure 1. Pluripotency of Embryonic Stem Cells. ESCs can differentiate to all 3 germs layers.
Several key transcription factors control stem cell pluripotency and renewal. With the suppression
of pluripotency markers and supplementation of chemical factors ESC can be pushed to a certain
cell lineage in vitro. Embryonic Stem Cell [Pluripotent: Embryonic stem cells are able to develop
into any type of cell, excepting those of the placenta. Only embryonic stem cells of the morula are
totipotent: able to develop into any type of cell, including those of the placenta.]. (n.d.). Retrieved
December 22, 2017, from https://en.wikipedia.org/wiki/Embryonic_stem_cell

Embryonic Stem Cell Test
To limit human exposure risk to hazardous environmental chemicals and
drugs, chemical compounds have been historically screened in rodents.
However, since the mid-20th century there has been a push to reduce the
amount of animal use and suffering for scientific purposes. The concept of the
7

Three R’s (Replacement, Reduction, and Refinement) outlined the importance of
refraining from animal use and when possible use in vitro and projection models
to perform experiments.18,19 A cellular approach allows safe, reliable, and high
throughput results. Three such approaches based on cells, the micromass whole
cell culture assay, the FETAX test (Frog Embryo Teratogenesis Assay-Xenopus),
and the Embryonic Stem Cell Test (EST)20 were validated in 2002 by the
European Centre for Validation of Alternative Methods (ECVAM) for accuracy
and predictivity. While all three were found potentially useful, only the EST
avoided the use of animal testing entirely. In addition to avoiding the sacrificial
use of animals, the EST is less laborious than other in vitro techniques and
requires less technical skill.
To classify potentially embryotoxic compounds the EST uses three
endpoints: i) Viability of 3T3 adult cells ii) viability of ESCs iii) differentiation
capability of ESCs to cardiomyocytes. ESCs are a good model for development
as gene expression during spontaneous differentiation into cardiomyocytes in
vitro mimics development in utero. Cell viability of cardiomyocytes is measured
via the MTT indirectly through metabolic activity, whereas differentiation is
determined by the amount of beating clusters using microscopy. Dose response
curves are developed, and half maximal activity is recorded for cytotoxicity (IC50)
and differentiation inhibition of cardiomyocytes (ID50). These results are then
incorporated into a bio-statistical model, where compounds and chemicals can
be classified into three categories based on their ability to induce developmental
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toxicity: Strongly embryotoxic, weakly embryotoxic, and non-embryotoxic.21,22
Validation studies on the EST to classify embryo-toxins compared in vitro to in
vivo data and found the EST had a 78% correct classification for the tested
compounds.
Improvement to the EST
The classical EST used cardiomyocytes as their differentiation capabilities
were spontaneously generated in vitro, though some exogenous factors can
have effects on specific tissues such as the central nervous system and leave
other organ and tissues unharmed.23 To expand the usefulness of the EST,
protocols to differentiate ESCs into a variety of tissues including neural, adipose,
and bone, were then subsequently developed.24,25
The zur Nieden lab has been instrumental in developing differentiation
protocols to drive cell commitment of human and murine embryonic stem cells
into chondrocytes and osteoblasts.24-26 To initiate differentiation, murine ESCs
are switched to culture conditions from which pluripotency factors are omitted.
Subsequent supplementation with the osteogenic specific factors 1,25(OH) 2
vitamin D3, β-glycerophosphate and ascorbic acid sends the cells down an
osteogenic path, during which the cells express a variety of bone markers in
sequence mimicking embryonic bone development. The final phenotypic
appearance of osteoblasts in culture is characterized by black appearing
deposits, which are made up of calcium.27
To improve the EST, additional technical endpoints were added such as
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RT-PCR and flow cytometry to concentrate on genes necessary for differentiation
into a specific cell lineage and standardize read-out.28 Another added benefit of
such techniques is that monitoring gene and protein expression can assess real
time regulation and provide temporal data specific for each chemical.
More recent alterations to the classical EST included the animal model
used in the experiment. The classical EST uses murine ESCs, though the use of
primate stem cells could abrogate the differences between species that have
been reported in toxicological studies. Zur Nieden and colleagues have provided
evidence that primate and human cells used in the EST are more sensitive to
certain compounds than their murine counterparts.29 In addition, the murine to
human switch also provides an additional advantage as human cells do not
require embryoid bodies to form during the experimental process. Human ESCs
can be grown and plated directly into culture plates, which allows less intrusion
during the experiment and eliminate the technically and laborious task of
performing the hanging drop method. Additionally, mature cell line used in the
EST was switched from mouse 3T3 cells to human foreskin fibroblasts (hFFs) to
better mimic the mother’s toxicological response during pregnancy.

Toxicology Priority Index
To prioritize chemicals for toxicity testing the Environmental Protection
Agency (EPA) in conjunction with the University of South Carolina at Chapel Hill
developed the Toxicology Priority Index (ToxPI) Graphical User Interface using
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data from aggregated database sources such as the EPA’s Tox21 and Toxcast.
The ToxPI system is a free downloadable prioritization support tool that can
evaluate the toxicity of a given chemical based on various sources of data and
can incorporate various data parameters that it integrates into a simple visual
representation in the form of a pie.30 The data compiled from various sources
such as in vitro assays are assimilated at the discretion of the user based on
preset and post modification settings in the ToxPI GUI.31 Each pie chart
produced by ToxPI is a depiction of one specific chemical, whereas the slices
that make up the pie chart are components or attributes of a chemical such as
chemical properties, biological pathways, and exposure data (Figure 2). These
slices in turn can be made of multiple smaller slices, which are representatives of
each assay or endpoint that is used. Each slice of the pie chart for each chemical
can also be given higher priority over other assays by giving more “weight” to a
specific assay and less weight to a non-specific assay thus effecting the size of
the pie charts.
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Figure 2. ToxPI Visualization Chart. ToxPI can incorporate data based off a variety of chemical’s
properties, bioactivity, and in vitro assay data. The various data parameters can then be
compared to one another and displayed as a visual pie chart. Those chemicals with the larger pie
charts have the highest predicted effects whereas the chemicals with smaller pie charts have a
smaller predicted effect. Bioinformatics. 2013 Feb 1; 29(3): 402–403. Published online 2012 Nov
29. doi: 10.1093/bioinformatics/bts686

Scaling can also be applied for each slice of a pie chart. In vitro data in the
ToxPI is given in micromolar concentration and scaling the data in
log10(x)+log10(max(x)) allows lower micromolar concentrations to result in larger
pie charts while higher micromolar concentrations producing smaller pie charts.31
ToxPI scaling is versatile and includes binary, zero to one “hit” and “non-hit”
systems, and linear scaling that allows smaller numbers to result in reduced pie
charts and larger numbers to result in greater pie charts. Scaling each slice
specifically for its data allows different slices to be compared to one another
despite each slice of a chemical’s pie chart representing different aspects its
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attributes.
The outcome of setting these different pathways not only produces a pie
chart visualization but takes in all information about a specific chemical and
reduces it to a unit-less number. In other words, each slice is ranked on a
dimensionless number system ranging from 0 to 1. A non-effective chemical slice
would have the least effect (0) and those with the highest predicted effects would
be given a 1. The total sum of every slice produces the overall ToxPI score. If a
chemical in ToxPI is composed of five slices those with the greatest effects would
not only be the biggest pie chart but would have the highest score (5) whereas
the lowest number would be 0 and the pie chart would be unfilled.
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Figure 3. Window Preview of ToxPI Data. Chemicals properties are divided by an individual color
and is turn made up of multiple smaller slices. For each color, appropriate scaling is applied for
every data set and conference intervals are calculated. Missing data % is shown in the middle of
each ToxPI and an overall ToxPI score is generated. Environ Health Perspect. 2010 Dec;
118(12): 1714–1720.Published online 2010 Sep 8. doi: 10.1289/ehp.1002180
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The ToxPI GUI produces a short summary for each of the calculated
chemicals. It gives vital information on the ToxPI score, its value broken up into
specific slices, how many chemicals are being ranked against each other and the
missing data in value percent. This value percent is also seen in the middle of
each ToxPI slice (Figure 3). Those with more grey or dark shades in the middle
of their ToxPI calculations have missing data. All chemicals are also visualized
on the same ToxPI plane and are given in a standard X, Y graph (not shown). In
this format, the standard deviations are shown between the chemicals and how
these could affect the chemicals rank. Y values represent the chemical ranks
whereas the X value represent the calculated ToxPI scores for each of the
chemicals.

The Interactive Chemical Safety and Sustainability Database
Data for the ToxPI software can be mined using the Aggregated
Computational Toxicology Online Resource (ACToR) database and can be easily
exported using the interactive Chemical Safety and Sustainability (iCCS) tab. The
interactive iCCS dashboard contains data from multiple database sources
including Toxicity Forecaster (Toxcast) and Toxicity Testing in the 21st century
(Tox21); the latter has been assimilating data since 2007. The iCCS houses data
on just over 9,076 chemicals and just under 1,200 assays. The data can be
filtered by different parameters such as a specific time points, specialized
tissues, cell type, and gene expression.
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Other information on bioactivity of chemicals are also available such as
human oral absorption and LogP values. The iCCS database assays are all
given in activity call (AC50) values, which are a superset of the classical known
50% inhibition of cytotoxicity and 50% inhibition of differentiation values. AC50
values are indicative of either inhibitory or activation effects. After filtering through
selected parameters at the discretion of the user the iCCS data can then be
exported via a downloadable excel workbook. The excel file then can be
reformatted to fit the ToxPI system and integrated into a matrix that can be
uploaded into the ToxPI program itself. ToxPI analysis has been useful in
assessing the ability of novel chemicals to disrupt endocrine receptors32, vascular
development and remodeling33, and evaluate risk associated with obesity and
diabetes.34

Aims and Objectives
Previous data from the zur Nieden lab (see chapter 3) points to an
inhibition of osteogenesis caused by various tobacco products. However, overall,
it is challenging to decipher how an individual chemical in tobacco smoke
contributes to toxicity or teratogenic effects during embryogenesis. A major
obstacle in studying these effects is the tobacco smoke itself, a concoction
composed of more than 7,000 chemical constituents. With the passage of the
Family Smoking and Prevention Act the Food and Drug Administration (FDA) in
2009 released a list of harmful and potentially harmful constituents (HPHCs) in
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tobacco products and tobacco smoke.36 While most of the chemical constituents
in tobacco smoke and products remain incompletely identified, the HPHC may
provide a good framework for focusing on those chemicals that pose the greatest
threat to human health. While the HPHC list has substantially reduced the
number of chemicals to test down to 97, testing these chemical constituents
individually or in assortments would be a time consuming and expensive venture.
Therefore, the specific objectives of this study will address the following two
specific aims.

Specific Aim 1: Use ToxPI as a prioritization tool to rank and predict chemical
constituents in tobacco products that can have cytotoxic and teratogenic effect
on skeletal development.
Specific Aim 2: Determine the toxicity of the highest predicted chemicals through
a well-established in vitro osteogenic protocol using human ESCs.
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CHAPTER TWO
MATERIALS AND METHODS

Materials
1.

mTESRTM 1 (Stem Cell Technologies, cat. no. 85850). mTESR medium was
sold as a kit that included basal medium and supplements. The medium was
completed when the supplements were added to the basal medium. Stored
at 2-8 °C.

2.

DMEM with 4500 mg D-Glucose/L (Stem Cell Technologies, cat. no. 36250).
Stored at 2-8 °C.

3.

Dulbecco’s Modified Eagle’s Medium and Ham’s F-12 Nutrient Mixture
(DMEM/F12) (ThermoFisher, cat. no. 11320-033). Stored at 2-8 °C.

4.

1X Phosphate Buffered Saline (PBS) without calcium, magnesium, or phenol
red, sterile, pH 7.4 (ThermoFisher, cat. no. 10010-023). Stored at 2-8 °C.

5.

Human embryonic stem cells (hESC), (e.g. H9 line from WiCell Research
Institute).

6.

Human foreskin fibroblasts (hFF) (ATCC, cat. no. CRL-2429™).

7.

2% gelatin, sterile cell culture grade (Sigma Aldrich, cat. no. G1393) Working
0.1% Gelatin: 2 mL of a 2% gelatin stock solution to 38 mL of pre-autoclaved
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sterile water. 0.1% gelatin was filtered using a 0.1 µm filter and stored at 28°C.
8.

Dimethyl Sulfoxide (DMSO) (Sigma, cat. no. 472301). Stored at room
temperature.

9.

Matrigel Matrix hESC (Stem Cell Technologies, cat. no. 354277). The 5 mL
vial of Matrigel matrix was thawed overnight at 2-8°C. Thawed matrigel
matrix was diluted 1:1 with 5 mL of cold DMEM/F12, and completely mixed,
and placed in 1 mL aliquots into 15 mL conical tubes. These aliquots were
stored at -20°C until needed. Working Matrigel: 1 mL of 1:1 diluted Matrigel
Matrix aliquot was thawed at 2-8°C and 14 mL of cold DMEM/F12 was
added. Working Matrigel can be stored at 2-8°C

10. Accutase, pre-made in Dulbecco's phosphate-buffered saline (DPBS) without
Ca2+ and Mg2+ (Innovative Cell Technologies, cat. no. AT-104). Stored at 2-8
°C.
11. Batch-tested fetal bovine serum (FBS). Stored at -20°C.
12. 100X MEM Non-Essential Amino Acid (NEAA) solution (Sigma, cat. no.
RNBD8621). Stored at 2-8 °C.
13. 10,000 U/mL Pencillin/Streptomycin (Lonza, cat. no. 17-602E). Stored at 2-8
°C.
14. 2-Mercaptoethanol (β-ME) (Gibco, cat. no. 21985). Stored at 2-8 °C.
15. Beta-Glycerophosphate (BGP) (Sigma, cat. no. 65422). A 1 M stock was
prepared by adding 10.802 grams into 50 mL of PBS and stored at -20°C.

19

16. 1-α, 25-(OH)2 vitamin D3 (Vitamin D3) (Sigma Aldrich, cat. no. 17936). A
stock of 50 mg/mL by adding 2.5 grams into 50 mL of PBS and stored at 20°C.
17. Ascorbic Acid (AA). (Sigma Aldrich cat. no. A4403). A stock concentration of
50 mg/mL was by adding 2.5 grams into 50 mL of PBS and stored at -20°C.
18. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
(Amresco, cat. no. 0982C140). A stock of 5 mg/mL MTT in 1X PBS was
prepared. The stock was sterile filtered using a 0.1 µm filter and stored at 20°C.
19. Sodium Dodecyl Sulfate (SDS) (Sigma Aldrich, cat. no. 436143). 20% SDS
solution can be made by adding 20 mL of SDS and 80 mL of PBS. Stored at
room temperature.
20. Isopropanol (Sigma Aldrich, cat. no. I9516). Stored at room temperature.
21. MTT Desorb: prepare MTT desorb solution containing 3.5% of 20% SDS and
96.5% isopropanol. Stored at room temperature.
22. NP-40 (abcam, cat. no. ab142227)
23. Sodium Deoxycholate (Sigma Aldrich, cat. no. D6750)
24. Radioimmunoprecipitation (RIPA) buffer. 1X PBS containing 0.1% SDS, 1%
25. NP-40 and 0.5% sodium deoxycholate. pH needs to be set to 7.2. Stored
at 2-8°C
25. Ca2+ reagent: 0.15 mM Arsenazo III (2,2’-bisbenzene-arsonic acid, DCL
Toronto). Ready-to-use reagent. Stored away from light at room
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temperature.
26. Calcium Carbonate (Fisher Scientific, cat. no. C63-10). A calcium stock
solution of 10 mg/mL in PBS was prepared and stored at 2-8°C.
27. Bovine Serum Albumin (BSA). Store powder at 2-8°C. A stock solution of 50
mg/mL in PBS was prepared and stored at 2-8 °C.
28. DC Protein Reagent Kit (Biorad, cat. no. 500-0111). When ready to use
1000µL of Reagent A was mixed with 25µL of Reagent S to make a new
solution A’. Stored away from light at room temperature.
29. 6-well non-treated cell culture plates (NEST Biotechnology, cat no. 703011).
30. 48-well non-treated cell culture plates (Cell Star, cat. no. 677102)
31. Absorbent underpads with waterproof moisture barrier (VWR, cat. no. 82020845) to be used as blotting paper.
32. Flat 96-well microtiter assay plates (e.g. Corning Costar).
33. Heidolph Polymax Wave Shaker (Brinkmann).
34. Refrigerated microcentrifuge, e.g. Eppendorf 5415R and 1.5 mL
microcentrifuge tubes (VWR, cat. no. 87004-262).
35. ELISA plate reader with filter sets for 550-570, 650 and 750 nm, e.g. Tecan
Safire 2™.
Media
1.

mTESRTM 1. Stored at 2-8°C.

2.

hFF medium: DMEM, 10% FBS, 1% NEAA and 0.5% of
Pencillin/Streptomycin. Stored at 2-8°C.
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3.

Control Differentiation Media (CDM): DMEM, 10% (FBS), 1% NEAA, 0.5% of
Pencillin/Streptomycin and 0.1 mM β-ME. Stored at 2-8°C.

4.

Osteogenic Differentiation Media (ODM): CDM media supplemented with 10
mM BGP, 50 mg/mL AA, and 50 mg/mL of Vitamin D3. Stored at 2-8°C.

Chemicals
1.

Nicotine (Toronto Research, cat. no. sc-N0267). Nicotine’s stock
concentration was made by diluting 5mg in 1mL of DMEM (5,000 µg/mL).
The stock concentration was filtered using 0.1 µm filters and stored at -20°C.

2.

Coumarin (Santa Cruz, cat. no. sc-205637). Coumarin’s stock concentrations
was made by diluting 50mg in 1mL of DMSO (50,000 µg/mL). The stock
concentration was stored at -20°C.

3.

Catechol (Santa Cruz, cat. no. sc-215763). Catechol’s stock concentration
was made by diluting 50mg in 1mL of water (50,000 µg/mL). The stock
concentration was filtered using 0.1 µm filters and stored at -20°C.

4.

Cotinine (Toronto Research, cat. no. C725000) Cotinine’s stock
concentration was made by diluting 5mg in 1.5mL of DMEM (1,292 µg/mL).
The stock concentration was filtered using 0.1 µm filters and stored at -20°C.

5.

Benz(a)anthracene (BAA) (Santa Cruz, cat. no. sc-252409). BAA’s stock
concentrations was made by diluting 50mg in 1mL of DMEM (50,000 µg/mL).
The stock concentration was stored at -20°C.

6.

Nicotelline (Toronto Research, cat. no. N401200). Nicotelline’s stock
concentration was made by diluting 5mg in 5mL of DMEM (5,000 µg/mL).
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The stock concentration was subsequently filtered using 0.1 µm filters and
stored at -20°C.
7.

Urethane (Sigma Aldrich, cat. no. U2500). Urethane’s stock concentration
was made by diluting 2,000mg in 6mL of DMEM (333,286 µg/mL). The stock
concentration was filtered using 0.1 µm filters and stored at -20°C.

8.

Quinoline (Sigma Aldrich, cat. no. 241571). Quinoline was stored at -20°C.

9.

Acrylamide (Sigma Aldrich, cat. no. 23701). Acrylamide was stored at -20°C.

10. N-formylnornicotine (NFN) (Toronto Research, cat. no. F700875). NFN’s
stock concentration was made by diluting 10mg in 1.5mL of DMEM (6,666
µg/mL). The stock concentration was filtered using 0.1 µm filters and stored
at -20°C.
11. 4-(N-Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) (Toronto
Research Chemicals, cat. no. M325750). NNK’s stock concentration was
made by diluting 10mg in 1mL of DMEM (10,000 µg/mL). The stock
concentration was filtered using 0.1 µm filters and stored at -20°C.
12. 4-(methylnitrosamino)-4-(3-pyridyl) butanal (NNA) (Toronto Research, cat.
no. M325650). NNA’s stock concentration was made by diluting 10mg in
1mL of DMEM (10,000 µg/mL). The stock concentration was filtered using
0.1 µm filters and stored at -20°C.
13. (R,S)-N-Nitrosoanatabine (NAT) (Toronto Research, cat. no. N524750).
NAT’s stock concentration was made by diluting 5mg in 1.5mL of DMEM
(3,330 µg/mL). The stock concentration was filtered using 0.1 µm filters and
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stored at -20°C.
Websites
ToxPI program was downloaded at http://comptox.unc.edu/toxpi.php. All
data was found at https://actor.epa.gov/actor/home.xhtml on the Toxicity
Forecaster (ToxCast) Dashboard link.

Methods
Toxicity Forecaster Data Mining
The Environmental Protection Agency’s Aggregated Computational
Toxicology online resource (ACToR) was accessed at
https://actor.epa.gov/actor/home.xhtml on September 20, 2017. The Toxicity
Forecaster (ToxCast) Dashboard link was selected and a new window
appeared. The chosen 17 chemicals were individually inserted into the chemical
name search bar. Chemicals were selected with the advanced search bar that
prompted an additional window to appear. Under “Filter assay using” biological
processes target was selected from the drop-down menu. From the on-value
section five biological processes were selected from drop-down menu: Cell
Death, Cell Proliferation, Cell Morphology, Oxidative Phosphorylation, and
Mitochondrial Depolarization. Selected chemical’s information was viewable
under the chemical and assays tabs and downloaded using the Export tab at the
top right corner of the browser. For each chemical the entire process was
repeated with a new window browser. All downloaded data was reformatted into
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a single excel csv. file for compatibility with the ToxPI GUI. The reformatted data
is shown below.

Table 1. Excel File Uploaded in ToxPI.

ToxPI Pie Chart Generation
The ToxPI GUI was downloaded at http://comptox.unc.edu/toxpi.php and
saved as a java application on the desktop. Data exported from the Toxicity
Forecaster was reformatted in an excel sheet and inserted into the ToxPI
program (download and format instructions above). The ToxPI GUI was opened
and the reformatted excel sheet was uploaded by the insert tab. In total,
seventeen chemicals were chosen manually and the generate charts icon was
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selected which allowed each of the biological processes to be sorted. The data
was sorted by the assays option and each assay option was named for each
biological process. For each assay option a corresponding data selection icon
appeared and data for each biological process was selected manually. Each
biological process was given its own unique color using the color bar; Cell
Morphology 2 assays (Green), Mitochondrial Depolarization 5 assays (Purple),
Oxidative Phosphorylation 8 assays (Yellow), Cell Death 27 assays (Black), and
Cell Proliferation 30 assays (Red).The 5 biological processes pie slices were
given scaling via scaling option by selecting -log10(x)+log10(max(x)) on the dropdown menu, this would ensure that lower active AC50 values were given
separation from non-active hits. Pie charts were generated by selecting final
generation tab and individualized pie charts were displayed on the screen. Pie
charts for all 17 chemicals were saved by selecting save images option. The
ToxPI images were saved individually and together.
Cell Passaging and Maintenance
hFF Culture Maintenance. hFFs were obtained from ATCC and were
grown in 0.1% gelatin pre-coated 6-well plates and kept at 37°C in a controlled
humidified 5% CO2 incubator. 6-well plates were pre-treated with 0.1% gelatin for
15 minutes before the start of passaging and subsequently removed. While in
culture hFFs were routinely checked for bacterial, yeast, and microbial
contamination using an inverted microscope. Cultures were also checked via the
inverted microscope for confluency. Cultures were considered confluent when
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hFFs covered 70% of the surface area of an individual 6-well and were passaged
in a 1:6 ratio. When a 6-well culture reached confluency hFF media was removed
and washed with PBS. PBS was subsequently removed and treated with 1mL of
Accutase. When hFFs dissociated and were suspended in solution, 1mL of hFF
media was added and consequently put in a 15mL conical tube and spun down
in a microcentrifuge. The supernatant was removed, and the left-over pellet was
resuspended in 6mL of hFF media. Each well of a 6-well plate was given 1mL of
the resuspended hFF cell suspension. hFFs were passaged every two to four
days when cells reached 70% confluency.
Human Embryonic Stem Cell Culture Maintenance. H9 hESCs were
obtained from WiCell. All human pluripotent cells were maintained in mTESR
media in pre-treated matrigel coated 6-well plates. 6-well plates were coated with
matrigel for 20-30 minutes and subsequently removed prior to the start of
passaging. hESCs were grown in an incubator at 37°C in a controlled 5% CO2
humidified incubator. While in culture cells were routinely checked for bacterial,
yeast, and microbial contamination using an inverted microscope. Cell
morphology was also assessed during this time to ensure pluripotency of the H9
cells. Cells that began to differentiate (fissured morphology) were discarded and
new H9s were used. 6-well cultures were assessed for confluency with an
inverted microscope and passaged when colonies covered 70% of the surface
area of an individual 6-well plate. Cells were also passaged when colonies grew
close to each other but were not touching. Cultures that reached confluency were
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passaged in a 1:6 ratio. Confluent culture’s mTESR media was removed and
washed with PBS. The PBS was removed, and cells were treated with 1mL of
Accutase. When colonies dissociated and were suspended in Accutase, 1mL of
mTESR was added and consequently put in a 15mL conical tube and spun down
in a microcentrifuge. The supernatant was removed and resuspended in 6mL of
mTESR. Each well of a 6-well plate was given 1mL of the resuspended cells in
mTESR. hESCs were passaged every two to four days as needed.
Cell Counting and Seeding. Seeding density was calculated from a 6-well
plate to a 48-well plate for the MTT and calcium endpoints. The surface area
ratio was calculated by dividing the area of 6-well plate over the surface area of a
48-well plate. The surface area ratio was multiplied by the passage ratio 1:6 to
obtain the dilution factor. The resuspended cell volume was divided over the
dilution factor and multiplied by 1000 to obtain the appropriate amount of cell
suspension needed per well of a 48-well plate. The cell suspension needed per
an individual 48-well was multiplied by the number of wells needed for the total
cell suspension. The total volume of media was calculated by the amount of
media (300µL) per individual 48-well multiplied by the number of wells. The total
cell suspension and total volume of media were mixed and 300µL was added to
each 48-well plate.
Osteogenic Differentiation and Endpoints
H9 hESCs were seeded into 48-well plates from a 6-well plate (Cell
counting and seeding instructions above). Cells were grown to 70% confluency
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and checked daily using the inverted microscope. When cells reached 70%
confluency or when colonies grew close to one another without touching the
differentiation protocol was started. mTESR medium was removed from each of
the wells and replaced with CDM. hESCs were given CDM until Day 5 where the
media was removed and replaced with ODM. Cells continued to grow in ODM
until Day 20. Media was replaced every 2-3 days during the differentiation
experiment.
Dilution Series. Cells from Day 0 to Day 20 were fed with a specific starting
concentration for each chemical, starting from the stock, each concentration was
made by subsequent serial dilutions (all chemicals tested were in a 10-fold
dilution series).
MTT Assay (Cell Viability). To determine cell viability hESCs and hFFs
were seeded (Cell counting and seeding instructions above) in separate 48-well
plates with 5 replicates for each test chemical concentration. hESCs were
differentiated into osteoblasts using our labs osteogenic protocol while hFFs
were fed hFF media during the entirety of the experiment. On day 20 cells were
supplemented with 50µL of PBS dissolved MTT for each well containing 300µL of
medium and placed inside an incubator for 2 hours in 5% CO2 atmosphere at
37°C under sterile conditions. After the 2-hour incubation period the 48-well
plates were placed upside down on blotting paper where the media was
absorbed and discarded. 325µL of MTT Desorb was added to each of the 48wells and placed on a micro-shaker for 15 minutes. 100µL of each well with MTT
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desorb was pipetted into a 96-well plate and the absorbance was read at 570nm
with a Bio-rad iMarkTM microplate reader. The percent cell viability was
calculated by normalizing treated wells with non-treated control wells.
Lowry Assay (Protein Determination). To determine protein content,
hESCs were seeded (Cell counting and seeding instructions above) in a 48-well
plate with 5 replicates for each test chemical concentration and differentiated into
osteoblasts using our labs osteogenic protocol. Upon collection (Day 20) CDM
media was removed and hESCs were washed with PBS. After the removal of
PBS, 300µL of RIPA buffer was added to each well and scrapped using a pipet
tip to dislodge the calcium from the base of the culture vessel. The scrapped
RIPA lysates were collected and placed into Eppendorf tubes. Protein standards
were prepared from the BSA stock solution in a 7 concentration serial dilution
series that ranged from 0.0 mg/mL – 1.5 mg/mL. 5µL of each BSA standard
concentration and RIPA collected lysates were placed into a 96-well plate.
Approximately 25µL of Reagent A’ was combined with RIPA lysates and BSA
concentrations and 200µL of Reagent B was subsequently added. The 96-well
plate was incubated for 15 minutes on a micro-shaker and absorbance was read
at 750nm on a Bio-rad iMarkTM microplate reader. Protein concentration was
determined by standardizing each well to the BSA protein concentration curve.
The curve was developed by graphing absorbance as the x-axis and the BSA
standard concentrations as the y-axis. A linear regression line was drawn with y
= m × x, where y= protein concentration in mg/mL, m = slope and x =
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absorbance. The mean blank was subtracted from all sample values and the total
protein content was calculated by multiplying the volume of the sample (0.3mL)
by the protein concentration in mg/mL.
Calcium Determination. The calcium assay was performed with the same
RIPA collected samples from the Lowry assay. A standard curve was developed
from the 10 mg/mL calcium stock solution for 8 concentrations in serial dilution
that ranged from 0.0 - 0.03 mg/mL Ca2+. 25µL of each calcium standard curve
concentration and RIPA collected lysates were placed into a 96-well plate.
Additionally, 75µL of Arsenazo III was added to each 96-well plate and
absorbance was read at 655nm with a Bio-rad iMarkTM microplate reader. The
calcium standard curve was drawn based off the values of the calcium standard
concentrations as the y-axis and absorbance as the x-axis. A linear regression
line (y = m × x) was drawn through 0 intercept where the slope was m,
absorbance as the x, and calcium concentrations in mg/mL as the y. The blank
value was subtracted from the sample values and total calcium content of each
sample was calculated by the volume of the sample multiplied (0.3mL) by the
calcium concentration in mg/mL. The total calcium content was normalized to the
total protein content that was measured with the Lowry assay. The untreated
wells were averaged and set to 100 percent and all values were calculated as
percentage of the untreated average. The mean and the standard deviation for
all test chemical concentrations were also calculated. The data was graphed with
the x-axis as the test chemical concentrations from low to high (left to right) and
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the y-axis as the percentage.
Classification of Tested Chemicals in the EST Biostatistical Model
The embryotoxic potential of the test chemical was calculated from the
IC50 and ID50 values. The IC50 and ID50 values were determined by graphical
estimation. The ID50 for the differentiation endpoint (hESCs) was put into relation
to the cytotoxicity endpoints (IC50 hESC and IC50 hFF) by insertion into three
linear discriminant functions.

I:

5.9157 log10 (IC50 hFF) + 3.500 log10 (IC50

II:

3.651 log10 (IC50 hFF) + 2.394 log10 (IC50

III:

−0.125 log10 (IC50 hFF) − 1.917 log10 (IC50

hESC)

hESC)

− 5.307

− 2.033

hESC)

IChFF−ID50 hESC
IC50 hESC

IChFF−ID50 hESC

+ 1.500

IC50 hESC

− 15.72

− 6.85

IChFF−ID50 hESC
IC50 hESC

− 2.67

A chemical was classified as non-embryotoxic agent when values
determined I>II and I>III (class I), as a weak embryotoxic agent (class II) if II>I
and II>III, and a strong embryotoxic agent (class III) when III>I and III>II.

32

CHAPTER THREE
PREVIOUS DATA

Osteogenic Protocol
Human ESCs were grown on matrigel coated plates and fed with mTESR
until they reached 70% confluency. Upon reaching confluency the media was
replaced with control differentiation media largely composed of Fetal Bovine
Serum (FBS) and Basal Medium Eagle Medium (DMEM). Cells were grown in
control differentiation media until day 5 when the medium was supplemented with
osteogenic factors 1-alpha,25 (OH)2 (Vitamin D3), ascorbic acid (AA), and betaglycerophosphate (BGP) (Figure 4A).
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Figure 4. Determination of Osteogenic Differentiation and Identity. (A) Schematic of the
osteogenic differentiation protocol. (B) Immunostaining with an osteocalcin antibody reveals
presence of bone matrix in the vicinity of black deposits. Alizarin Red S staining detected calcium
ions in the same areas. (C) Quantitative measurement of deposited calcium over time, n=5
independent replicates ± SD, *P<0.05 Student’s t test compared to d0. (D) Quantitative mRNA
analysis of RUNX2, SATB2 and OCN, normalized to GAPDH (n=3 independent samples ± SD),
*P<0.05 One-Way ANOVA over day 0. Triplicates were pooled for RT-PCR analyses of the
osteocyte genes CAPG and DESTRIN (inset). Unpublished data.

Osteocalcin, a protein that is secreted by osteoblasts into the extracellular
matrix of bone was identified in cultures. Likewise, Alizarin Red S further
confirmed the calcification of the ECM another hallmark as the result of
osteoblast formation (Figure 4B). Calcium deposition were shown to increase
throughout 30 days of the osteogenic differentiation (Figure 4C). Quantitative
mRNA confirmed the presence of RUNX2, an early osteogenic marker that
controls other osteogenic markers, SATB2 an osteogenic progenitor marker, and
OCN a mature osteoblast marker (Figure 4D). CapG and Destrin presence are
indicative that osteoblasts are maturing into osteocytes.
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Tobacco Exposure and Osteogenesis
The lab next tested the effects of tobacco on osteogenic differentiation.
Among the tested products were two conventional cigarettes, one additive-free
variety and two so-called ‘Light’ cigarettes. Both mainstream (MS) smoke, which
is what the smoker inhales, and side-stream (SS) smoke, which burns off the tip
of the cigarette, were tested. The conventional products caused no significant
change in cell viability or calcification for any of the tested concentrations (Figure
5A). In contrast, the conventional side stream smoke showed a decrease in cell
viability and calcification, with both curves overlapping (Figure 5B), suggesting
that the differentiation defect was caused by the cytotoxicity of the product.
While the additive-free cigarette smoke extract behaved similarly as the
conventional products did, the two harm-reduction cigarettes exhibited very
different patterns. Harm-reduction SS smoke caused a significant decrease in
calcification already at sub-toxic concentrations (Figure 5D). This poses a
significant issue for in utero exposures since it implies that surviving cells are
defective potentially resulting in developmental abnormalities for the fetus during
pregnancy. This truly teratogenic effect was seen also in MS smoke of the harmreduction brands, albeit at high concentrations. These results let us conclude that
harm-reduction cigarettes may be more detrimental to the developing fetus than
conventional cigarettes.
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Figure 5. Determining Osteogenic Toxicity in Conventional and Light Camel Cigarettes. Human
ESCs were treated with different concentrations of MS smoke solution and scored for effects on
calcium deposit using Arsenazo III and on viability using an MTT assay. A) Camel MS smoke
solution. B) Camel SS smoke solution. C) Camel Blue MS smoke solution. D) Camel Blue SS
smoke solution. Each data point is the mean of three independent experiments ± standard
deviation. ΔP<0.05 = lowest concentration significantly below the untreated control in the calcium
assay determined by One-Way ANOVA. *P<0.05 = lowest concentration significantly below the
untreated control in the MTT assay on H9 hESCs determined by One-Way ANOVA. hESC,
human embryonic stem cell; MS, mainstream; MTT, mitochondrial dehydrogenase activity assay;
SS, side-stream. Unpublished data.
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CHAPTER FOUR
RESULTS

ToxPI Development and Production
Of the 93 chemicals on the FDA’s tobacco products and smoke HPHC list
only 46 were found in the Toxicity Forecaster database. With the intention of
making ToxPI parameters specific to osteogenesis a variety of genes necessary
for bone development were examined in the Toxicity Forecaster. Genes such as
Frzzld, CatB, and FoxO paramount to osteogenesis were incomplete for each of
the remaining 46 tobacco constituents. Using incomplete data sets introduced
large margins of errors in the ToxPI prediction model and were not useful for
meaningful analysis. Other chemical properties such as oral absorption was
absent for the targeted chemicals. To use ToxPI as a useful prioritization tool it
was then decided to use biological processes as the driving data parameter. This
shortened our remaining HPHC list of 46 chemicals to 17. Biological processes
are normal functions that all cells must undergo to be viable. Though these
parameters are broad and not osteogenically specific, their inclusion would be
appropriate as any perturbations of these biological processes could alter cell
fate and differentiation capabilities of hESCs.24
Furthermore, additional parameters were implemented. Row 1 data on the
reformatted excel sheet was given a value of 1 to ensure equal weight among
assays and biological processes. Each assay was also renamed in Row 5 to its
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corresponding biological process. To predict long term exposure 24, 48, and 72hour assays were used where shorter duration assays were disregarded. All
assays were further optimized to include human cell lines for a variety of tissues
and non-human animal data was excluded to avoid species-to-species
differences in chemical sensitivities. Each biological process was given its own
unique color (Figure 6) and scaling was applied to each of data sets to ensure
that lower AC50 values were indicative of bigger pie charts where larger values
produced smaller visualizations. Out of the 17 ToxPI predictive pie charts 8
chemicals generated ToxPI positive results where 9 of the chemicals did not
produce a visualization (Figure 7).

Biological Process

Weight

Components

Cell Proliferation (Red)

Data
Type
Assay

1

30

Cell Death (Black)

Assay

1

27

Oxidative
Phosphorylation
(Yellow)
Mitochondrial Depolarization
(Purple)
Cell Morphology (Green)

Assay

1

8

Assay

1

5

Assay

1

2

Figure 6. ToxPI Integrated Components. Each biological process was given its own pie chart slice
(5) based off assay data and had equal weight. In total, 72 assays encompassed all five
biological process slices. Each slice was then given its own color; Cell Proliferation (Red), Cell
Death (Black), Oxidative Phosphorylation (Yellow), Mitochondrial Depolarization (Purple), and
Cell Morphology (Green).
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Figure 7. ToxPI Generated Charts. ToxPI charts were generated for 17 chemicals using 72 in
vitro assays across 5 biological processes. Benz(a)anthracene (3.251), Benzo(b)fluoranthene
(2.137), Catechol (2.15), Napthalene (1), Nitrobenzene (.457), Coumarin (.451), Acetamide
(.391), Quinoline (.107), and N-Nitrosodimethylamine (.102) had designated “hits” and produced
positive ToxPi values (0< X). The remainder of the chemicals 2,6 Dimethylaniline, Acrylamide,
Nitrososodiethylamine, Nicotine, Cotinine, Phenol, o-cresol, p-cresol, and Urethane had ToxPI
predicted null effects (X=0).

To compare the predicted value assigned to each chemical using ToxPI
with its actual cytotoxicity and skeletal toxicity, we next chose a set of chemicals
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to test in vitro using the human EST that the lab had established previously. We
chose these chemicals at random from ToxPI positive and ToxPI negative
chemicals. The randomly selected ToxPI positive chemicals were BAA with the
highest ToxPI predictive score of 3.717, catechol with the second highest score
of 2.982, coumarin, which received the fourth highest score of 0.451, and
quinolone, whose penultimate ToxPI positive score value was 0.107. The
randomly selected ToxPI null chemicals were nicotine (0), cotinine (0),
acrylamide (0), and urethane (0) (Figure 7).

Human EST In Vitro Data for ToxPI Positive Chemicals
BAA and Catechol’s hFF cell line did not exhibit a loss in cell viability in
the same range as their H9 counterparts (Figure 8). Quinoline’s hFF cell viability
was reduced at concentrations a hundred-fold higher than their H9 counterparts
whereas coumarin’s hFF cell viability was reduced within the same range as its
H9 immature cell line. All four ToxPI constituents showed dose response curves
of H9 cell viability and calcification following similar trends, it is believed that the
decrease in calcification is an attributed consequence of the overall reduction in
viable cells. BAA was calculated to have a 200 µg/mL H9 hESC ID50/IC50,
catechol’s H9 hESC ID50/IC50 was 0.1 µg/mL, coumarin received a H9 hESC
ID50/IC50 of 20 ug/mL, and quinoline’s H9 hESC ID50/IC50 was 5.5 µg/mL. (Figure
8). All tested ToxPi charts were able to predict immature H9 cytotoxicity, though
the potency of the compound could not have been assessed by looking at the
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size of each predicted pie chart.
When assessing the average assay hit rate for each of the ToxPI tested
chemicals, the ToxPI score and size for each pie chart varied between chemicals
as did the average micromolar concentration for each chemical constituent. This
discrepancy became less apparent when the assay hit rate was converted from
micromolar into micrograms per microliter (Figure 9). Interestingly, the predictive
value of each assay hit rate in µg/mL was relatively close to our in vitro H9 hESC
ID50/IC50 (Figure 9).
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Figure 8. Determination of Skeletal Teratogenicity for ToxPI Positive Chemicals. Dose response
curves for ToxPI positive Benz(a)anthracene, Catechol, Coumarin, and Quinoline. The three
endpoints for the osteogenic EST; Cell Viability (MTT) of H9 hESC and hFF, and differentiation
potential via assessment of calcium deposits are shown.
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BAA

Coumarin

Catechol

Quinoline

AC50 hit µM Average

47.04

62.51

14.70

67.80

AC50 hit µg/mL
Average

10.73

9.86

1.16

8.76

H9 hESC ID50/IC50
µg/mL

200 ± 76

20 ± 10

0.01 ± .005

2 ± 1.5

Figure 9. Toxicity Forecast Data Averages and In Vitro H9 hESC ID50/IC50 µg/mL Values. The
average assay hit value in µM (AC50) values for each tested ToxPI positive constituent obtained
from the Toxicity Forecaster database. The AC50 in µM for was then converted into µg/mL in
comparison to the H9 hESC ID50/IC50 values calculated from the in vitro osteogenic screen.

Human EST In Vitro Data for ToxPI Negative Chemicals
Four ToxPI null chemicals (nicotine, cotinine, urethane, and acrylamide)
were also taken through the osteogenic EST (Figure X). ToxPI predicted null
effects matched in vitro screen data as urethane, cotinine, nicotine, and
acrylamide exposure did not inhibit cell viability for either the H9 and hFF cell
lines for all tested concentration ranges (Figure 10). Likewise, H9 hESC
differentiation potential was not altered in the same concentration range for
urethane, cotinine, and acrylamide. However, a notable decrease in calcification
(Figure 10) was seen in the higher concentrations of nicotine exposure.
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Figure 10. Determination of Skeletal Teratogenicity for ToxPI Null Chemicals. Dose response
curves for ToxPI null Nicotine, Cotinine, Acrylamide, and Urethane. The three endpoints for the
osteogenic EST; Cell Viability (MTT) of H9 hESC and hFF, and differentiation potential via
assessment of calcium deposits are shown.

Toxicity Predictions Based on the EST Biostatistical Model
All tested chemicals hFF IC50 and H9 hESC ID50/IC50 values were
incorporated into the EST bio-statistical model as outlined in classification of
tested chemicals in the EST Bio-Statistical Model. All in vitro tested ToxPI
positive pie charts were classified as weakly or strongly embryotoxic, whereas all
in vitro tested ToxPI null predicted chemicals were classified as non-embryotoxic.
Coumarin and BAA were classified as weakly embryotoxic where catechol and
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quinoline received a strongly embryotoxic compound status (Figure 11). The
discrepancy between strongly and weakly embryotoxic seemed to have been
attributed to the IC50 value found for the cell viability in fully differentiated hFFs in
relation to those found with the undifferentiated H9 cell line.

Chemical
Name

ToxPI
Prediction

hFF (IC50)
Cytotoxicity

hESC (IC50)
Cytotoxicity

hESC (ID50)
Differentiation

EST
Classification

BAA

+

—

200 ± 76

200 ± 76

Weakly
Embryotoxic

Catechol

+

—

0.1 ± 0.05

0.1 ± 0.05

Strongly
Embryotoxic

Coumarin

+

65 ± 26

20 ± 10

20 ± 10

Weakly
Embryotoxic

Nicotine

-

—

—

0.32 ± 3

NonEmbryotoxic

Cotinine

-

—

—

—

NonEmbryotoxic

Urethane

-

—

—

—

NonEmbryotoxic

Quinoline

+

100 ± 85

2 ± 1.5

2 ± 1.5

Strongly
Embryotoxic

Acrylamide

-

—

—

—

NonEmbryotoxic

Figure 11. Toxicity Classification in the EST Biostatistical Model. ToxPI predictions are listed
along H9 and hFF cell viability in addition to differential potential of H9 hESCs into osteoblasts.
The following ID50 and IC50 were incorporated into a bio-statistical model and classified as either
Non-Embryotoxic, Weakly Embryotoxic, or Strongly Embryotoxic.

Third Hand Smoke Constituents
Third hand smoke (THS) constituents are the residue and particulate
matter that persists long after a cigarette has been ignited. THS lifespan can
range from several weeks to months and because of its interaction with the
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environment can be more volatile as it ages. THS remain an understudied
component of tobacco products and many of the chemical constituents in the
HPHC largely list mainstream and side stream components. We found it of great
importance to study the individual constituents that make up THS through our
EST osteogenic protocol. The chemicals that were selected have been shown to
persist in carpet after several months.37 In addition, these selected THS
constituents are on the FDA’s HPHC list and makes them prime candidates to be
tested. These constituents however were not included in the ToxPI analysis due
to a lack of sufficient assay availability in the Toxicity Forecaster database.
Nicotelline’s H9 hESC cell viability decreased in a similar trend with
calcification, this similarity in dose response curves is likely a consequence from
reduction of viable cells. Thus, an h9 hESC IC50 of >200 µg/mL was estimated.
The adult line also decreased in the same concentration range and produced an
hFF IC50 of >200 µg/mL. NFN, NAT, and NNK did not display cytotoxicity in the
adult hFF or immature H9 cell line (Figure 12). Differentiation potential into
osteoblast was also not inhibited in the same concentrations range for the tested
chemicals. Though the hFF cell viability remained inert for NNA through all
concentrations, a significant reduction in H9 cell viability and calcification was
seen at the highest tested concentration of (4.8 x 10-4 µg/mL) (Figure 12). When
grouped in ternary combination THS constituents Nicotelline, NNA, and NNK cell
viability and calcification was further reduced than each chemical constituent
could induce individually (Figure 13).
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Figure 12. Determination of Skeletal Teratogenicity for Third Hand Smoke Constituents. Dose
response curves for THS constituents Nicotelline, (R,S)-N-Nitrosoanatabine (NAT), NFormylnornicotine (NFN), 4-(methylnitrosamino)-4-(3-pyridyl) butanal (NNA), and 4-(N-Methyl-Nnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). The three endpoints for the osteogenic EST; Cell
Viability (MTT) of H9 hESC and hFF, and differentiation potential via assessment of calcium
deposits are shown.
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Figure 13. Cell Viability and Calcification of a Ternary Combination of THS Constituents. Three
THS constituents; Nicotelline, NNA, and NNN were subjected in tandem to our osteogenic
protocol. H9 hESC cell viability (MTT) and differentiation potential via assessment of calcium
deposits are shown.
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CHAPTER FIVE
DISCUSSION

ToxPI Predictions and In Vitro Data
Toxcast iCCS has over 11,000 chemicals and 21,000 assays available,
though there was a lack of endpoints and gene targets relating to osteogenesis
available in the online database. We decided to use biological processes to help
predict cytotoxicity as the partition between cytotoxicity and teratogenicity is
indistinguishable in vivo.24 Other factors were thought to be included in addition
to using biological processes’ AC50 values (Assay hit rate) but incorporating LogP
values38 and Z-scores39 may have not corrected potential false negatives and
have been shown to remove pie charts that reflected true positives in ToxPI
predictions.
The selected data used from Toxcast across the 72 assays and 5
biological processes were heavily geared towards cytotoxicity. This is due to 52
of the 72 biological processes’ assays exclusively measuring cell proliferation or
cell death. The assays excluded non-human cell types and multitude of cell
lineages ranging from Human Embryonic Kidney (HEK) cells to umbilical vein
endothelium. With this range in cell types it was likely that the H9 hESC IC50
values that were obtained in our in vitro screen would fall in the range of AC50
values that were available in the Toxcast. In addition to cell types, the chosen
assay time endpoint excluded more short-term assays such as a one-hour
49

exposure time to focus on potential cytotoxic and teratogenic effect that are part
of long-term exposure. The assays tested range from 0 µM to 1000 µM. The
maximum threshold of 1000 µM to micrograms per milliliter can be readily
converted by looking at a chemical’s molecular weight. The eight tested
chemicals max threshold ranged from 60 µg/mL to 228 µg/mL. Without
consideration for max thresholds ToxPI predicted null pie charts could seemingly
provide false negatives for chemicals whose cytotoxic and teratogenic effects are
induced above the predictive threshold.
Acrylamide’s ToxPI null prediction were for concentrations up to 71 µg/mL
where cytotoxic and differentiation inhibition was seen at concentrations greater
than 100 µg/mL (data not shown). Likewise, urethane’s ToxPI null predicted chart
were for concentrations up to 89 µg/mL where cytotoxic effects were seen at
extreme exposure concentrations (1000 µg/mL, data not shown).
The in vitro tested ToxPI positive chemicals (BAA, Coumarin, Catechol,
Quinoline) all varied in the number of “hits” for the incorporated assays. BAA and
catechol had the highest amount of assay “hits” with catechol having slightly
more than BAA. BAA’s higher ToxPI score was predominantly based on its ability
to have hits in all five of the biological process in addition to having the most
sensitive AC50 value. The average AC50 value for each tested ToxPI positive
constituent ranged from 14 µM- 67 µM, however, when converted into
micrograms per microliter this discrepancy diminished, and all ToxPi positive
tested chemicals fell within a 10 microgram per microliter range of each other.
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This small threshold could explain why ToxPI positive chemicals H9 hESC IC50
values were similar despite having different ToxPI predictive chart sizes. This
would also suggest that our ToxPI positive visualizations are more an indicator
on the likelihood of producing a cytotoxic event within a given concentration
range rather than a ranking system for potent cytotoxic constituents.
There was an uncanny consistency between the Toxcast data that was
implemented into the ToxPI GUI. For all ToxPI positive predictive charts there
was not a reliable assay that provided a hit among the predictive constituents
even among each of the biological processes. This variability did not inhibit the
ability to predict cytotoxic effects. Though, it would be beneficial to include
validated assays such as the MTT for cell death or Bromodeoxyuridine (BrdU) for
cell proliferation. Because the Toxicity Forecaster data was generated using
high-throughput screening these may not be feasible options as most of the
assays were luminescence based and automated, but including data from these
assays when available, as well as incorporating data from previous studies could
provide stronger confidence in ToxPI predictions. The incorporation of previously
reported data in conjunction with Toxcast data has been successful in ranking
chemical constituents based on ability to reduce gill size in zebrafish. 33
Our only ToxPI null predicted chemical to produce a half-maximal value
was the most famous chemical constituent in tobacco and tobacco related
products: nicotine. Nicotine is a powerful neurotoxin that interacts with
acetylcholine receptors and can alter brain development, though its effects are
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largely dependent on duration, dose, and habitual use.40-42 Nicotine has been
shown to have dose-dependent inhibition on cell viability and proliferation for a
variety of tissues43 though there are conflicting studies regarding the ability of
nicotine to impede cell viability. However, in non-neural cells it can activate
antagonistic cell survival and death pathways, though the precise mechanism of
choosing one biological process over another is not clear.44 This can resolve the
discrepancy between contradicting results of the cytotoxicity associated with
nicotine and explain why both our adult and immature cell viabilities were
maintained through all tested concentrations.
In contrast, the role nicotine plays in osteogenesis is transparent as its
dose-dependent inhibition is documented in a variety of studies.45-47 Though
ToxPI had a variety of parameters to predict the cytotoxicity of nicotine,
osteogenic endpoints were not able to be integrated into the ToxPI predictive
model. Therefore, differentiation inhibition did not produce a visualization on the
ToxPI chart of nicotine in contrast to our EST in vitro data.

EST Biostatistical Model Versus ToxPI Predictions
All in vitro tested chemicals were incorporated into the EST bio-statistical
model. The model then classified each of the compounds based on their ability to
induce embryotoxicity. This classification gave insight into little known effects of a
chemical’s exposure. Alongside each chemical in the FDA’s HPHC list are
categories that classify each chemical as a Carcinogen (CA), Respiratory
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Toxicant (RT), Cardiovascular Toxicant (CT), Reproductive or Developmental
Toxicant (RDT), or Addictive (AD).48 All tested chemicals were given a CA
classification on the HPHC list except for nicotine, that was classified as both an
AD and RDT. Our data suggests that in addition to a CA classification both
quinoline and catechol are RDTs. This is especially alarming as our H9 hESC
IC50 catechol levels can be reasonably reached from smoking 1-2 cigarettes.49
Nicotine was calculated to have an H9 hESC ID50 value with no changes in cell
viability for the immature and mature cell lines but was listed as a nonembryotoxic compound. Embryotoxicity in the EST is defined as the adverse
effects on the embryo expressed as embryonic cell death to one or more body
systems that can be expanded to maternal health. This is a limitation of the EST,
though it can classify embryotoxic effects the EST biostatistical model cannot
classify chemicals who are teratogenic at sub-toxic levels.50
ToxPI predicted AC50 and in vitro h9 hESC’s IC50 values corresponded well
with numerous in vivo tests. Coumarin’s toxicity in zebrafish51 and Xenopus52
provided half-maximal activity values for viability that were adjacent to both our
own hESC and hFF IC50. Likewise, quinoline is reported to induce a variety of
malformations and toxicity between 29-95 ug/mL depending on the
developmental stage of Xenopus53 where the median lethal dose for other
aquatic species has been reported to be 11 ug/mL.54 Catechol had a variety of
animal models55,56 with toxic concentrations similar to our own and it
corroborated with other independent in vitro data.57 BAA also had exposure
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values that resulted in the death of zebrafish larvae slightly lower than our
results.58
For our tested ToxPI null chemicals none of our concentrations were
detrimental to cell viability of our H9 hESC. Cotinine levels in blood of chronic
smokers is 500 ng/mL, light smokers are from 30-50 ng/mL, whereas 1-10 ng/mL
and concentrations below the 1 ng/mL threshold are regarded as low.59 Our
study tested far above these biologically relevant thresholds and found no
inhibitory effects. Urethane (ethyl carbamate) in other toxicological studies only
induced a reduction in cell viability at excessively high concentrations. 60 These
concentrations however are a thousand times greater than can be encountered. 61
Acrylamide exposure for rat and murine NR-50 levels (midpoint toxicity)62 were
relatively close to our IC50 values when excluding ToxPI maximum threshold for
both H9 and hFF cells. Acrylamide’s cytotoxicity in this concentration range
seems to be prevalent for both in vitro and in vivo studies using a variety of
animal models.63,64 Though the estimated dietary concentration of acrylamide is
around 1µm for the average adult65 and additional acrylamide exposure in
cigarettes raises the dietary levels by only three times the amount. 66 Though our
data suggests a differentiation inhibition capability of nicotine during
osteogenesis these levels are not biologically relevant as they are not achieved
in arterial blood67 after smoking and in extreme cases are as high as 0.1
µg/mL.68-70
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Overall, ToxPI predictions based on the parameters we have set forth are
likely indicators of reduced H9 cell viability and can partition between chemicals
that induce and do not induce cytotoxic events when tested in ToxPI predictive
thresholds. ToxPI may lack sensitivity to detect sub-toxic effects, but as
implemented in our study lacks a predictive component for osteogenesis.
Though, our parameters may be altered to incorporate genes and pathways that
can predict the inhibition of other differentiation processes that are available on
the Toxicity Forecaster database. There are potential pitfalls that can arise from
the ToxPI system, however, with an ever-growing database and subsequent
improvements it can be a useful resource in assessing the ability of a chemical to
impact early embryonic development.

THS EST and Combination Testing
THS as a new emerging threat to human health has garnered much
attention in the last decade.71 The main source of THS is attributed to nicotine as
it is absorbed by the surface and reacts with nitrous acid (HONO) species in
addition to ultraviolet light and other ambient species.72 However, this is not
applicable to all THS constituents as NAT is a non-nicotine derived tobacco
constituent that is primarily derived from anatabine and anabasine. THS extracts
from carpets exposed to cigarette smoke have confirmed the presence of NNK,
NNA, NAT, and NFN.37 Each of the chemicals were found to have increased
concentrations as smoking persisted and found the highest concentrations of
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THS constituents were found at 12 months of exposure. Surprisingly, THS
constituents are not exclusive to cigarette combustion. Studies have shown that
NNN and NNK concentrations were higher in homes occupied by smokeless
tobacco users than in tobacco-free homes.73 This is alarming as THS levels
seem to increase with the use of tobacco products regardless of how the
products is consumed. This also raises new concerns as cleaning methods such
as vacuuming are ineffective in the removal of THS constituents from the
environment.
Early efforts into the potential health outcomes of THS focused on
genotoxicity and carcinogenicity. These early studies reported THS constituents
NNN and NNK to induce DNA damage in human cells at biologically relevant
concentrations and subsequently led to their classification as carcinogens.74
Furthermore, in vivo studies have shown THS to reduce the weight and immunity
of mice in the absence of carcinogenicty.75 There have been several attempts to
assess the toxicity of THS constituent’s in vitro as THS terry cloth extracts have
demonstrated the ability to inhibit mouse neural stem cell survival as well as
mature human fibroblast.76 NNK has also demonstrated the ability to inhibit lung
tissue repair, though there are no experiments that have solely focused on a
specific developmental process. To our knowledge we are the first to test the
toxicity of NFN and NAT, and Nicotelline using a differentiation protocol.
Three of our THS constituents (NAT, NFN, NNK) did not hinder cell
viability or differentiation in the tested concentrations. This suggests that the
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screened THS constituents may be non-embryotoxic compounds. Individually,
the tested THS constituents themselves may not be cytotoxic but there is strong
evidence that THS possess combinatorial effects. For example, NNK
synergistically reacts with NNN to produce deleterious effects increasing their
capability to induce double strand DNA breaks.77 Like many chemical
concoctions, THS effects appear to be dose-dependent but its effects on various
development processes are still not clear. NNA produced a decrease in cell
viability for hESC suggesting embryotoxicity at relatively low concentrations. This
inhibition of cell viability is within range of NNA concentrations found in the
homes of continuous smokers, where these reported findings gave NNA
concentrations modest estimations.78
Further studies should be done to assess the synergistic effects of THS
during embryogenesis. Our lab has done early experiments that suggest many
chemicals constituents exhibit a stronger effect on development when used in a
ternary combination. Though the full spectrum of the ability of THS to cause
potential harm during pregnancy and the early years of childhood are not fully
known, we have demonstrated that the THS constituent NNA poses a potential
health concern other than carcinogenicity.
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CHAPTER SIX
CONCLUSIONS

A Framework for Toxicity Testing in the Future
Narrowing down the primary drivers of the chemical mixture that
encompasses tobacco products and smoke remains a large challenge. This
study has found that using the ToxPI program in conjunction with Toxcast data
can partition cytotoxic constituents from those that will produce no harm within
their predictive range. This is especially useful as many tobacco constituents are
encountered in the agricultural and pharmaceutical sector. Furthermore, because
our parameters inserted into the ToxPI GUI were broad, they can be applied to
various products who are made up of a concoction of chemicals and is not limited
to those chemicals in tobacco products and smoke. Though the parameters
chosen to generate the ToxPI charts were not specific to the osteogenic lineage,
their testing in a well-established protocol was a recapitulation of osteogenic
development during gastrulation. With the assimilation of Toxcast data in its
infancy, the database has the potential to grow and could have data available in
the future to help predict osteogenic maldevelopment specifically as seen
currently with other target tissues.
With the limitations of available data for HPHC chemicals and the
emergence of a new potential threat in the form of THS we found it of great
importance to test constituents through the osteogenic protocol. Our data
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suggests that the tested THS constituents individually are not all cytotoxic but
could still pose great harm in tandem with other tobacco related chemicals.
Overall, because there are many routes of exposure to tobacco products even
among non-users, it is of importance to incorporate data when available from
high-throughput sources to make conclusions about the toxicity and
developmental effects a chemical constituent can produce.
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